Novo Nordisk celebrates positive trial results for oral semaglutide in teens while facing first generic Ozempic competition in Canada, as stock slides 41% year-over-year.<\/p>\n
The Danish drugmaker is simultaneously celebrating a clinical win in pediatrics while grappling with the first generic assault on its blockbuster franchise in a G7 nation. Novo Nordisk\u2019s latest moves reveal a company racing to diversify its portfolio before the patent cliff arrives.<\/p>\n
A phase 3a trial dubbed \u201cPIONEER TEENS\u201d has delivered compelling results for oral semaglutide in adolescents with type 2 diabetes. After 26 weeks, patients saw a statistically significant 0.83% reduction in long-term blood sugar compared to placebo. The safety profile mirrored that seen in adult studies, with no unexpected side effects. Research chief Martin Holst Lange framed the pill as a critical option for younger patients whose blood sugar remains uncontrolled on standard therapies.<\/p>\n
Novo Nordisk plans to file for regulatory approval in the US and Europe during the second half of this year. If cleared, it would become the first GLP-1 therapy in pill form approved for this age group\u2014a strategic moat against the generic erosion already underway in adult markets.<\/p>\n
Yet even as management prepares those submissions, the competitive landscape is shifting. Canada\u2019s health authority has approved the first generic version of semaglutide, manufactured by Dr. Reddy\u2019s Laboratories. That makes Canada the first G7 country to allow a direct copy of Ozempic, opening a price war on Novo Nordisk\u2019s home turf. The move compounds pressure from the US, where the FDA recently greenlit a daily weight-loss pill from a major rival.<\/p>\n
Should investors sell immediately? Or is it worth buying Novo Nordisk?<\/a><\/p>\n The company is also making headway in rare diseases. Phase 3 data for denecimig, a treatment for hemophilia A, showed a 99% reduction in bleeding rates with monthly dosing. That outperformed existing preventive treatments, which saw a 43% reduction. Novo Nordisk filed for US approval last September. The rare-disease push comes amid broader industry consolidation\u2014the Chiesi Group just snapped up KalVista for $1.9 billion on Wednesday.<\/p>\n Investors, however, are fixated on the core business. The stock closed at \u20ac34.55 on Wednesday, down roughly 23% year-to-date. On a 12-month basis, the decline stretches to over 41%. The relative strength index has sunk to 24.9, signaling deeply oversold conditions. Over the past month, the shares have clawed back nearly 10% to \u20ac34.76, but that recovery remains fragile.<\/p>\n The next catalyst arrives on May 6, when Novo Nordisk reports first-quarter earnings. Analysts forecast earnings per share of $0.87. A share buyback program worth up to 15 billion Danish kroner is providing some floor under the stock.<\/p>\n